Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients Anne-Laure Roux, Emilie Catherinot, Nathalie.

Slides:

Advertisements

Similar presentations

Mycobacterium avium and Mycobacterium abscessus complex target distinct cystic fibrosis patient subpopulations Emilie Catherinot, Anne-Laure Roux, Marie-Anne.

Advertisements

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Bacterial contamination in the environment of hospitalised children with cystic fibrosis Agnès Ferroni, Aurélie Werkhauser-Bertrand, Muriel Le Bourgeois,

Persistent Bordetella bronchiseptica infection in a child with cystic fibrosis: Relationship to bacterial phenotype Nevine El Khatib, Agnes Ferroni,

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Cystic fibrosis mortality trends in France

Mycobacterial peritonitis: difference between non-tuberculous mycobacteria and Mycobacterium tuberculosis C.-C. Shu, J.-T. Wang, J.-Y. Wang, C.-J. Yu,

Pancreatic enzyme replacement therapy for young cystic fibrosis patients Anne Munck, Jean-Francois Duhamel, Thierry Lamireau, Bernard Le Luyer, Claire.

Causes of death in French cystic fibrosis patients: The need for improvement in transplantation referral strategies! Clémence Martin, Cécile Hamard,

E. Cambau, M. Drancourt Clinical Microbiology and Infection

Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis M. Proesmans, F. Vermeulen,

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of.

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

John Widger, Sarath Ranganathan, Philip J. Robinson

Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection Marita Gilljam, Henrik Scherstén, Martin Silverborn, Bodil.

The ease of breathing test tracks clinical changes in cystic fibrosis

Pulmonary exacerbations in CF patients with early lung disease

Increasing nontuberculous mycobacteria infection in cystic fibrosis

Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,

Controlled clinical trials in cystic fibrosis — are we doing better?

Factors associated with subsequent nontuberculous mycobacterial lung disease in patients with a single sputum isolate on initial examination M.-R. Lee,

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Amyloidosis in cystic fibrosis: A case series

Charles R. Esther, Denise A

C. O'Driscoll, J. Konjek, B. Heym, M. M. Fitzgibbon, B. J. Plant, M

A.H. Gifford Journal of Cystic Fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Physiologic endpoints for clinical studies for cystic fibrosis

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis Christopher R. Sudfeld, Elliott C. Dasenbrook, William.

Cytokine gene polymorphisms and severity of CF lung disease

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance P. Goncalves-Vidigal,

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients E.B. Wilms, D.J. Touw, H.G.M. Heijerman

D.Y.F. Mak, J. Sykes, A.L. Stephenson, L.C. Lands

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Paternity in men with cystic fibrosis: a retrospective survey in France Ingrid Duguépéroux, Dominique Hubert, Stéphane Dominique, Gil Bellis, Marc De.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

A simplified, semi-quantitative structural lung disease computed tomography outcome during quiet breathing in infants with cystic fibrosis Magali Saguintaah,

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

Risk factors for Mycobacterium abscessus infection in cystic fibrosis patients; a case– control study Maarten Verregghen, Harry G. Heijerman, Monique.

C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

CFTR modulators and pregnancy: Our work has only just begun

Treatment intensity and characteristics of MRSA infection in CF

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non p.Gly551Asp gating mutations treated with ivacaftor

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Anne K. Swisher, Kathryn Moffett, Linda Baer

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Cystic fibrosis and pregnancy in the modern era: A case control study

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients Anne-Laure Roux, Emilie Catherinot, Nathalie Soismier, Beate Heym, Gil Bellis, Lydie Lemonnier, Raphaël Chiron, Brigitte Fauroux, Muriel Le Bourgeois, Anne Munck, Isabelle Pin, Isabelle Sermet, Cristina Gutierrez, Nicolas Véziris, Vincent Jarlier, Emmanuelle Cambau, Jean-Louis Herrmann, Didier Guillemot, Jean-Louis Gaillard Journal of Cystic Fibrosis Volume 14, Issue 1, Pages 63-69 (January 2015) DOI: 10.1016/j.jcf.2014.07.004 Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 BMI Z-score in the M. massiliense and M. abscessus groups. Journal of Cystic Fibrosis 2015 14, 63-69DOI: (10.1016/j.jcf.2014.07.004) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Kinetics of mean BMI Z-score in the M. massiliense and M. abscessus groups. 0 is the year of the first mycobacterial isolation. Journal of Cystic Fibrosis 2015 14, 63-69DOI: (10.1016/j.jcf.2014.07.004) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Number of positive MABSC cultures and AFB smear positivity in cases with or without MABSC lung disease. AFB smear-positive cases were all cases with at least one positive AFB smear. Samples were obtained for a minimum period of 18months. Patients with a positive NTM sample had to submit three more sputum samples at monthly interval and then every 3months. Journal of Cystic Fibrosis 2015 14, 63-69DOI: (10.1016/j.jcf.2014.07.004) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 4 Evolution of FEV1 in treated eradicated patients and treated non-eradicated patients in the M. massiliense and M. abscessus groups. Graphs are represented with individual curves. 0 is the year of first mycobacterial isolation. Journal of Cystic Fibrosis 2015 14, 63-69DOI: (10.1016/j.jcf.2014.07.004) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions